<!doctype html>
<html lang="es">
<head>
<meta charset="utf-8" />
<meta name="viewport" content="width=device-width, initial-scale=1" />
<title>Spanish Daily – Dec 9, 2025</title>
<meta name="color-scheme" content="light dark" />
<style>
  :root { --maxw: 800px; }
  html { -webkit-text-size-adjust: 100%; }
  body { margin: 0; padding: 0; font-family: system-ui,-apple-system,Segoe UI,Roboto,Helvetica,Arial,sans-serif,Apple Color Emoji,Segoe UI Emoji; line-height: 1.6; font-size: 18px; }
  header, main, footer { max-width: var(--maxw); margin: 0 auto; padding: 16px; }
  header { padding-top: 20px; }
  h1 { font-size: 1.4rem; margin: 0 0 8px; }
  .subtle { opacity: 0.72; font-size: 0.95rem; }
  .card { border: 1px solid rgba(0,0,0,0.08); border-radius: 12px; padding: 14px; margin: 12px 0; }
  .tip-word { all: unset; display: inline; position: relative; cursor: pointer;
    text-decoration: underline dotted; text-underline-offset: 3px;
    padding: 0 .1em; border-radius: .35em; background: rgba(255,235,59,.28); }
  .tooltip { position: fixed; padding: .48rem .6rem; background: rgba(0,0,0,.88); color: #fff;
    border-radius: .55rem; font-size: .95rem; line-height: 1.3; max-width: min(90vw, 26rem);
    z-index: 9999; box-shadow: 0 6px 18px rgba(0,0,0,.18); }
  .content { white-space: pre-line; }
  .card { margin-bottom: 1.5em; line-height: 1.6; }
  strong { display: inline-block; margin-top: .35em; }
  details { border: 1px solid rgba(0,0,0,0.08); border-radius: 12px; padding: 12px; }
  details + details, details + .card { margin-top: 12px; }
  summary { cursor: pointer; font-weight: 600; }
  summary::marker { content: ""; }
  summary::after { content: " ▸"; }
  details[open] summary::after { content: " ▾"; }
  .debug { position: fixed; bottom: 8px; right: 8px; font-size: 12px; opacity: .6; }
</style>
</head>
<body>
  <header>
    <h1>Spanish Daily</h1>
    <div class="subtle">Toca una palabra subrayada para ver la traducción. Toca fuera para cerrar.</div>
  </header>

  <main>
    <!-- Spanish first -->
    <section class="card content">
STORY

Los <span title="bispecific">anticuerpos biespecíficos</span> que <span title="activate T lymphocytes">activan linfocitos T</span> ahora <span title="are used earlier">se usan más temprano</span> en la <span title="pediatric B-cell ALL">LLA de células B pediátrica</span>. Nuevos datos <span title="show that they can change">muestran que pueden cambiar</span> el <span title="management of minimal residual disease">manejo de la enfermedad mínima residual</span> (EMR) y, en algunos casos, <span title="modify transplant plans">modificar los planes de trasplante</span>.

<span title="Blinatumomab has">Blinatumomab cuenta con</span> aprobaciones de la EMA y la FDA para <span title="children with relapsed or refractory B-cell precursor ALL">niños con LLA de precursores de células B en recaída o refractaria</span>, y para <span title="B-ALL positive for MRD in complete remission">LLA B positiva para EMR en remisión completa</span>. En el estudio COG AALL1331, <span title="blinatumomab achieved">blinatumomab logró</span> una <span title="better disease-free survival">mejor supervivencia libre de enfermedad</span> y una <span title="deeper MRD clearance">eliminación más profunda de la EMR</span> que la <span title="intensive chemotherapy">quimioterapia intensiva</span> en la <span title="first relapse">primera recaída</span>.

En la <span title="standard-risk B-ALL according to the NCI">LLA B de riesgo estándar según el NCI</span>, los <span title="randomized data from">datos aleatorizados del</span> COG AALL1731 <span title="presented at">presentados en</span> ASH y ASCO <span title="show that adding">muestran que agregar</span> blinatumomab a la quimioterapia <span title="improves MRD negativity">mejora la negatividad de EMR</span> y los <span title="early disease control outcomes">resultados tempranos de control de la enfermedad</span>. También <span title="allows doctors to reduce">permite a los médicos reducir</span> la <span title="total exposure to chemotherapy">exposición total a la quimioterapia</span>.

En la <span title="first high-risk relapse">primera recaída de alto riesgo</span>, la <span title="blinatumomab-based consolidation">consolidación basada en blinatumomab</span> en AALL1331 <span title="resulted in">resultó en</span> más <span title="MRD-negative remissions">remisiones negativas para EMR</span> y menos <span title="allogeneic hematopoietic stem cell transplant procedures">procedimientos de trasplante alogénico de células madre hematopoyéticas</span> (TCMH) que la <span title="chemotherapy alone">quimioterapia sola</span>.

<span title="Early-phase pediatric data">Datos pediátricos en fases tempranas</span> para otros biespecíficos, como los <span title="CD3×CD19 and CD3×CD22 constructs">constructos CD3×CD19 y CD3×CD22</span>, <span title="show activity in">muestran actividad en</span> LLA B con <span title="intensive prior treatments">tratamientos previos intensivos</span>. Sin embargo, el <span title="initial use with little or no chemotherapy">uso inicial con poca o ninguna quimioterapia</span> <span title="remains experimental">sigue siendo experimental</span>.

Las <span title="toxicities such as">toxicidades como</span> el <span title="cytokine release syndrome">síndrome de liberación de citocinas</span> (CRS), la <span title="neurotoxicity">neurotoxicidad</span> y las <span title="infections are usually manageable">infecciones suelen ser manejables</span> y, <span title="often less severe than">a menudo, menos graves que</span> con CAR-T. <span title="Even so">Aun así</span>, <span title="they require standard grading">requieren clasificación estándar</span> y <span title="early treatment with">tratamiento temprano con</span> tocilizumab o esteroides.

<span title="Therefore">Por lo tanto</span>, los <span title="first-line protocols">protocolos de primera línea</span> para LLA B pediátrica <span title="should use blinatumomab">deben usar blinatumomab</span> como un <span title="key agent">agente clave</span> <span title="targeting MRD">dirigido a la EMR</span> y para <span title="consolidation">consolidación</span>, con <span title="chemotherapy reduction guided by trials">reducción de quimioterapia guiada por ensayos</span> y <span title="careful use of">uso cuidadoso del</span> TCMH.

---
DIALOGUE

Narrator: <span title="Today we talk about">Hoy hablamos sobre</span> un <span title="new treatment for">nuevo tratamiento para</span> la LLA de células B en niños.
Physician: Hola. <span title="We have a new medicine">Tenemos un nuevo medicamento</span> para tu leucemia. <span title="It's called">Se llama</span> blinatumomab.
Patient: <span title="Is it like">¿Es como</span> la quimioterapia de antes?
Physician: <span title="It's different">Es diferente</span>. <span title="It helps your T lymphocytes">Ayuda a tus linfocitos T</span> <span title="to find and destroy">a encontrar y destruir</span> las <span title="cancer cells">células cancerosas</span>.
Patient: <span title="Will I still need">¿Todavía necesitaré</span> un <span title="bone marrow transplant">trasplante de médula ósea</span>?
Physician: <span title="Maybe not">Tal vez no</span>. <span title="This medicine can make">Este medicamento puede hacer que</span> el cáncer <span title="becomes very small">sea muy pequeño</span>, o <span title="even disappear">incluso desaparezca</span>. <span title="You might not need">Puede que no necesites</span> un trasplante.
Patient: <span title="Does it have side effects">¿Tiene efectos secundarios</span>?
Physician: Sí, <span title="you can have">puedes tener</span> fiebre, <span title="tiredness or headache">cansancio o dolor de cabeza</span>. <span title="Most are not serious">La mayoría no son graves</span>. <span title="We monitor you closely">Te vigilamos de cerca</span>.
Patient: <span title="Is it safer than">¿Es más seguro que</span> otros tratamientos?
Physician: <span title="It can be safer than">Puede ser más seguro que</span> la <span title="strong chemotherapy">quimioterapia fuerte</span> o CAR-T. <span title="Even so">Aun así</span>, <span title="we must monitor">debemos vigilar</span> las infecciones y <span title="treat side effects quickly">tratar los efectos secundarios rápidamente</span>.
Patient: <span title="Can I go home earlier">¿Puedo irme a casa antes</span>?
Physician: <span title="Sometimes, yes">A veces, sí</span>. <span title="If you feel well">Si te sientes bien</span> y <span title="don't have major side effects">no tienes efectos secundarios importantes</span>, <span title="you can spend less time">puedes pasar menos tiempo</span> en el hospital.
Patient: <span title="Am I going to lose my hair">¿Voy a perder el cabello</span>?
Physician: <span title="This medicine normally does not make">Este medicamento normalmente no hace que</span> se <span title="hair falls out">caiga el cabello</span> como la quimioterapia.
Narrator: <span title="Blinatumomab helps more children">Blinatumomab ayuda a que más niños</span> <span title="achieve MRD-negative remissions">alcancen remisiones negativas para EMR</span> con <span title="fewer side effects">menos efectos secundarios</span>.
    </section>

    <!-- English below -->

    <details open class="card content">
      <summary>INGLÉS</summary>
STORY

Bispecific T-cell–engaging antibodies are now used earlier in pediatric B-cell ALL. New data show they may change MRD care and, in some cases, change transplant plans.

Blinatumomab has EMA and FDA approvals in children with relapsed/refractory B-cell precursor ALL and for MRD-positive B-ALL in complete remission. In COG AALL1331, blinatumomab gave better disease-free survival and deeper MRD clearance than intensive chemotherapy in first relapse.

In NCI standard-risk B-ALL, randomized COG AALL1731 data from ASH and ASCO show that adding blinatumomab to chemotherapy improves MRD negativity and early disease-control outcomes. It also lets doctors lower total chemotherapy exposure.

In high-risk first relapse, blinatumomab-based consolidation in AALL1331 led to more MRD-negative remissions and fewer allogeneic HSCT procedures than chemotherapy alone.

Early-phase pediatric data for other bispecifics, such as CD3×CD19 and CD3×CD22 constructs, show activity in heavily pretreated B-ALL. But frontline chemo-light or chemo-free use is still investigational.

Toxicities like CRS, neurotoxicity, and infections are usually manageable and often less severe than with CAR-T. They still need standard grading and early tocilizumab or steroids.

So, frontline pediatric B-ALL protocols should use blinatumomab as a key MRD-directed and consolidation agent, with trial-guided chemotherapy de-escalation and careful HSCT use.

---
DIALOGUE

Narrator: Today we talk about new treatment for B-cell ALL in children.
Physician: Hello. We have new medicine for your leukemia. It is called blinatumomab.
Patient: Is it like the old chemo?
Physician: It is different. It helps your T-cells find and kill cancer cells.
Patient: Will I still need a bone marrow transplant?
Physician: Maybe not. This medicine can make the cancer very small, or even gone. You may not need a transplant.
Patient: Does it have side effects?
Physician: Yes, you can get fever, tiredness, or headaches. Most are not very bad. We watch you closely.
Patient: Is it safer than other treatments?
Physician: It can be safer than strong chemo or CAR-T. We still must watch for infection and treat side effects fast.
Patient: Can I go home early?
Physician: Sometimes, yes. If you feel well and have no big side effects, you may spend less time in the hospital.
Patient: Will I lose my hair?
Physician: This medicine does not usually make hair fall out like chemo does.
Narrator: Blinatumomab helps more children reach MRD-negative remissions with fewer side effects.
    </details>
  </main>

  <footer class="subtle">
    <div>© Dec 9, 2025 · Mezra.AI · Practica todos los días.</div>
  </footer>

  <div class="debug">EN: found</div>

  <!-- NEW: light cache-busting helper -->
  <script>
  (function() {
    // 1. Get the version tag from the URL, if present (?v=SHA...)
    var params = new URLSearchParams(window.location.search);
    var version = params.get('v');

    // 2. Read the debug indicator already inside your page
    var debug = document.querySelector('.debug');
    var debugText = debug ? debug.textContent.trim() : '';

    // 3. Heuristic: if version is missing or debug looks suspicious, force a one-time reload
    var isLikelyStale =
      !version ||
      debugText === '' ||
      debugText.indexOf('placeholder') !== -1 ||
      debugText.indexOf('not found') !== -1 ||
      debugText.length < 3;

    if (isLikelyStale) {
      if (!params.get('forceReload')) {
        params.set('forceReload', '1');
        var newUrl = window.location.pathname + '?' + params.toString();
        window.location.replace(newUrl);
      }
    }
  })();
  </script>

  <!-- Existing tooltip behavior -->
  <script>
  (function () {
    document.querySelectorAll('.content').forEach(function(container) {
      container.querySelectorAll('span[title]').forEach(function(span) {
        var text = span.textContent;
        var tip  = span.getAttribute('title');
        var btn  = document.createElement('button');
        btn.className = 'tip-word'; btn.type = 'button';
        btn.textContent = text; btn.setAttribute('data-tip', tip);
        span.replaceWith(btn);
      });
    });

    var openTip = null;
    function closeTip(){ if(openTip){ openTip.remove(); openTip = null; } }
    function showTip(target){
      closeTip();
      var tipText = target.getAttribute('data-tip') || '';
      if(!tipText) return;
      var bubble = document.createElement('div');
      bubble.className = 'tooltip';
      bubble.textContent = tipText;
      document.body.appendChild(bubble);
      var r = target.getBoundingClientRect();
      var m = 8, vw = innerWidth, vh = innerHeight;
      var rect = bubble.getBoundingClientRect();
      var tw = rect.width;
      var th = rect.height;
      var left = r.left, top = r.bottom + m;
      if (left + tw + m > vw) left = Math.max(m, vw - tw - m);
      if (left < m) left = m;
      if (top + th + m > vh) top = Math.max(m, r.top - th - m);
      bubble.style.left = left + 'px';
      bubble.style.top  = top + 'px';
      openTip = bubble;
    }

    document.addEventListener('click', function(e) {
      var word = e.target.closest('.tip-word');
      if (word){ if (openTip) closeTip(); else showTip(word); e.stopPropagation(); }
      else { closeTip(); }
    });
    document.addEventListener('touchstart', function(e) {
      if (!e.target.closest('.tip-word')) closeTip();
    }, { passive: true });
    addEventListener('scroll', closeTip, { passive: true });
    addEventListener('resize', closeTip);
    document.addEventListener('keydown', function(e) { if (e.key === 'Escape') closeTip(); });
  })();
  </script>
</body>
</html>